Position of the Transparency Council – Ferriprox (deferiprone)

At its meeting on 2 September 2024, the Transparency Council adopted position No. 87/2024 on the legitimacy of issuing approvals for reimbursement of the drug Ferriprox (deferiprone) for the indication: neurodegeneration with iron deposition in the brain.

Publication of the position >>